Skip to main content
. 2021 Apr 2;113(10):1352–1359. doi: 10.1093/jnci/djab065

Figure 1.

Figure 1.

Trial profile. *Adverse events indicate grade 3 and 4 events; †Other reasons except for adverse events. EC-wP = epirubicin/cyclophosphamide followed by weekly paclitaxel; EP-wP = epirubicin/paclitaxel followed by weekly paclitaxel; ITT, intention to treat.